Chinmaya Rath
Corporate Officer/Principal en GLYCOMIMETICS, INC. .
Fortuna: 43 679 $ al 31/05/2024
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Gregorio Guillen | M | - |
Catena Biosciences, Inc.
 Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | 4 años |
| Rachel King | F | 64 | 21 años | |
| Marco Lobba | M | - |
Catena Biosciences, Inc.
Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | 4 años |
| Matthew B. Francis | M | - |
Catena Biosciences, Inc.
Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | 4 años |
| Timothy Pearson | M | 56 | 10 años | |
| Harout Semerjian | M | 52 | 3 años | |
| Daniel Junius | M | 71 | 8 años | |
| Scott Jackson | M | 59 | 6 años | |
| Scott Koenig | M | 71 | 7 años | |
| Mark Goldberg | M | 69 | 10 años | |
| Peter Bruce-Clark | M | - |
Social Impact Capital, Inc.
 Social Impact Capital, Inc. Investment ManagersFinance Social Impact Capital LLC (Social Impact) is a Venture Capital firm founded in 2015 by Sarah Cone. The firm is headquartered in New York. | 6 años |
| Patricia Andrews | F | 66 | 7 años | |
| Sarah Cone | F | - |
Social Impact Capital, Inc.
Social Impact Capital, Inc. Investment ManagersFinance Social Impact Capital LLC (Social Impact) is a Venture Capital firm founded in 2015 by Sarah Cone. The firm is headquartered in New York. | 8 años |
| Christian B. Dinneen-Long | M | - | 5 años | |
| Brian Hahn | M | 49 | 14 años | |
| Edwin Rock | M | 63 | 2 años | |
| Bruce Johnson | M | 56 | 2 años | |
| Stephanie R. Irish | F | 53 | 10 años | |
| Lisa V. DeLuca | M | - | 3 años | |
| Meg Wood | F | - |
Catena Biosciences, Inc.
Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | 2 años |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Estados Unidos | 20 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Chinmaya Rath
- Red Personal
